Abstract SY25-02: RNA as a cancer driver: Recurrent ZC3H18 mutations stabilize oncogenic endogenous retroviral transcripts

Abstract Metastatic melanoma remains a major cause of cancer mortality, underscoring the need to uncover new therapeutic vulnerabilities. Tumor genomic sequencing reveals that nuclear RNA surveillance genes are mutated in a substantial fraction of melanomas, implicating dysregulated RNA metabolism as a potentially important, but still underexplored, driver of tumorigenesis. ERVs and related remnants of ancient viral infections comprise ∼8% of the human genome. Although ERV RNAs trigger immune activation, they are the most abundantly expressed repeat elements in many cancers, suggesting that they provide a selective advantage despite potential immunostimulatory costs. Across multiple cancer types, we identified that ZC3H18 (Z18)—a nuclear RNA surveillance component—is mutated or lost in ∼30% of all cancers and that Z18 has recurrent truncating mutations. We show that Z18 truncating (Z18trunc) mutations are oncogenic and that Z18 plays an evolutionarily conserved role in nuclear surveillance of oncogenic ERV RNA. In zebrafish, Z18trunc accelerated melanoma onset and selectively increased ERV RNA. Z18-mutant CCLE human cancer cell lines and TCGA patient tumors also upregulated ERV RNA. In engineered human melanoma cells, Z18trunc enhanced ERV RNA accumulation more than loss of one Z18 allele, indicating dominant-negative activity. Z18trunc directly stabilized and relocalized ERV RNA to the cytoplasm. Functionally, expression of Z18-regulated zebrafish or human ERV RNA was sufficient to accelerate melanoma in zebrafish and is required for Z18trunc-mediated zebrafish melanoma and human melanoma cell growth. Together, these findings establish a direct, functional role for ERV transcripts in cancer and identify aberrant RNA accumulation—via disrupted nuclear RNA surveillance—as a broad mechanism of oncogenesis and a potential therapeutic vulnerability Citation Format: Tanzina Tanu, Anna Cox, Jennifer Karlow, Priyanka Sharma, Kaiwen Sun, Xueyang He, Andrew McCallion, Kevin Brown, Stephen Chanock, David Liu, Tongwu Zhang, Kathleen Burns, Paul Boutz, Megan L. Insco. RNA as a cancer driver: Recurrent ZC3H18 mutations stabilize oncogenic endogenous retroviral transcripts [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr SY25-02.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-17
DOI
https://doi.org/10.1158/1538-7445.am2026-sy25-02
Primary Topic
Melanoma and MAPK Pathways
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract SY25-02: RNA as a cancer driver: Recurrent ZC3H18 mutations stabilize oncogenic endogenous retroviral transcripts

Xueyang He, Megan L. Insco, Paul L. Boutz, Tanzina Tanu et al.
Cancer Research
Melanoma and MAPK Pathways
article

Abstract SY25-02: RNA as a cancer driver: Recurrent ZC3H18 mutations stabilize oncogenic endogenous retroviral transcripts

Xueyang He, Megan L. Insco, Paul L. Boutz, Tanzina Tanu, Andrew S. McCallion, Priyanka Sharma, Jennifer A. Karlow, Kevin Brown, David Liu, Kaiwen Sun, Kathleen Burns, Stephen J. Chanock, Tongwu Zhang, Anna Cox
article en

Abstract

Abstract Metastatic melanoma remains a major cause of cancer mortality, underscoring the need to uncover new therapeutic vulnerabilities. Tumor genomic sequencing reveals that nuclear RNA surveillance genes are mutated in a substantial fraction of melanomas, implicating dysregulated RNA metabolism as a potentially important, but still underexplored, driver of tumorigenesis. ERVs and related remnants of ancient viral infections comprise ∼8% of the human genome. Although ERV RNAs trigger immune activation, they are the most abundantly expressed repeat elements in many cancers, suggesting that they provide a selective advantage despite potential immunostimulatory costs. Across multiple cancer types, we identified that ZC3H18 (Z18)—a nuclear RNA surveillance component—is mutated or lost in ∼30% of all cancers and that Z18 has recurrent truncating mutations. We show that Z18 truncating (Z18trunc) mutations are oncogenic and that Z18 plays an evolutionarily conserved role in nuclear surveillance of oncogenic ERV RNA. In zebrafish, Z18trunc accelerated melanoma onset and selectively increased ERV RNA. Z18-mutant CCLE human cancer cell lines and TCGA patient tumors also upregulated ERV RNA. In engineered human melanoma cells, Z18trunc enhanced ERV RNA accumulation more than loss of one Z18 allele, indicating dominant-negative activity. Z18trunc directly stabilized and relocalized ERV RNA to the cytoplasm. Functionally, expression of Z18-regulated zebrafish or human ERV RNA was sufficient to accelerate melanoma in zebrafish and is required for Z18trunc-mediated zebrafish melanoma and human melanoma cell growth. Together, these findings establish a direct, functional role for ERV transcripts in cancer and identify aberrant RNA accumulation—via disrupted nuclear RNA surveillance—as a broad mechanism of oncogenesis and a potential therapeutic vulnerability Citation Format: Tanzina Tanu, Anna Cox, Jennifer Karlow, Priyanka Sharma, Kaiwen Sun, Xueyang He, Andrew McCallion, Kevin Brown, Stephen Chanock, David Liu, Tongwu Zhang, Kathleen Burns, Paul Boutz, Megan L. Insco. RNA as a cancer driver: Recurrent ZC3H18 mutations stabilize oncogenic endogenous retroviral transcripts [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr SY25-02.

Cancer ResearchVol. 86(8_Supplement)
Johns Hopkins University (US), Dana-Farber Cancer Institute (US), National Cancer Institute (US), University of Rochester (US), University of Baltimore (US)
Good health and well-being
Openalex Percentile: Top 19%
Melanoma and MAPK Pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.